Reolysin Doubles Survival Rates of P53-mutated Metastatic Breast Cancer Patients Receiving Taxol, Study Finds
News
Women with mutated p53 metastatic breast cancer lived twice as long when treated with Reolysin plus Taxol (paclitaxel) compared to those who received Taxol alone, according to the randomized, IND 213 Phase ... Read more